Publications

How can the public health impact of vaccination be estimated?.

Echeverria-Londono, S; Li, X; Toor, J; De Villiers, MJ; Nayagam, S; Hallett, TB; ABBAS, K; JIT, M; KLEPAC, P; Jean, K; Garske, T; Ferguson, NM; Gaythorpe, KA M;

2021

BMC Public Health, (2021).21 1 10.1186/s12889-021-12040-9.

Migration and outbreaks of vaccine-preventable disease in Europe: a systematic review.

Deal, A; Halliday, R; Crawshaw, AF; HAYWARD, SE; Burnard, A; Rustage, K; Carter, J; Mehrotra, A; Knights, F; Campos-Matos, I; Majeed, A; Friedland, JS; Edelstein, M; MOUNIER-JACK, S; Hargreaves, S; European Society of Clinical Microbiology and Infe,;

2021

The Lancet Infectious Diseases, (2021).21 12 10.1016/S1473-3099(21)00193-6.

Factors influencing acceptance of vaccination during pregnancy in The Gambia and Senegal.

JOHM, P; Nkoum, N; Ceesay, A; Mbaye, EH; LARSON, H; KAMPMANN, B;

2021

Vaccine, (2021).39 29 10.1016/j.vaccine.2021.05.068.

Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics.

NKURUNUNGI, G; ZIRIMENYA, L; NATUKUNDA, A; Nassuuna, J; Oduru, G; Ninsiima, C; Zziwa, C; Akello, F; Kizindo, R; Akello, M; KALEEBU, P; WAJJA, A; Luzze, H; COSE, S; WEBB, E; ELLIOTT, AM; POPVAC trial team,;

2021

BMJ open, (2021).11 2 10.1136/bmjopen-2020-040425.

Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study.

Li, X; MUKANDAVIRE, C; Cucunubá, ZM; Echeverria Londono, S; ABBAS, K; Clapham, HE; JIT, M; Johnson, HL; Papadopoulos, T; VYNNYCKY, E; Brisson, M; Carter, ED; CLARK, A; De Villiers, MJ; Eilertson, K; Ferrari, MJ; Gamkrelidze, I; Gaythorpe, KA M; Grassly, NC; Hallett, TB; Hinsley, W; Jackson, ML; Jean, K; Karachaliou, A; KLEPAC, P; ... Vaccine Impact Modelling Consortium,

2021

The Lancet, (2021).397 10272 10.1016/S0140-6736(20)32657-X.

Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study.

Chan, J; Gidding, HF; Blyth, CC; Fathima, P; Jayasinghe, S; McIntyre, PB; Moore, HC; MULHOLLAND, K; Nguyen, CD; Andrews, R; Russell, FM;

2021

PLoS medicine, (2021).18 8 10.1371/journal.pmed.1003733.

Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.

Debellut, F; CLARK, A; Pecenka, C; Tate, J; Baral, R; SANDERSON, C; Parashar, U; Atherly, D;

2021

The Lancet. Global health, (2021).9 7 10.1016/S2214-109X(21)00167-4.

A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars.

Olsen, AW; Rosenkrands, I; HOLLAND, MJ; Andersen, P; Follmann, F;

2021

NPJ vaccines, (2021).6 1 10.1038/s41541-021-00312-9.

Better data for country-level TB resource allocation are urgently required.

Clarkson, MC; MCQUAID, CF; HOUBEN, RM; KRANZER, K; WHITE, RG;

2021

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, (2021).25 8 10.5588/ijtld.20.0912.

Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries.

FU, H; ABBAS, K; KLEPAC, P; VAN ZANDVOORT, K; TANVIR, H; Portnoy, A; JIT, M;

2021

BMC Medicine, (2021).19 1 10.1186/s12916-021-02157-4.